Good play on a speculative migraine pain management device.
Around 600 M shares outstanding with low float and virtually no debt.

A small investment in ADHC could yield exponential returns in a few short years.
Market cap could exceed to over 11B+ with successful FDA and clinical studies then successful marketplace execution.

Over $1 PPS is not unreasonable with this massive pain management market.

Good luck to longs.
Beyond Technical AnalysisChart PatternsLONGOTCpennystockTrend Analysis

Disclaimer